Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA known ✓ | P10253 | 4/20 | 0.36 |
| ▸ | GLA known ✓ | P06280 | 2/20 | 0.36 |
| ▸ | ABL1 known ✓ | P00519 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.39 |
| ▸ | CFTR | P13569 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.37 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | HPGD | P15428 | 3/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | CASP1 | P29466 | 1/20 | 0.36 |
| ▸ | CASP7 | P55210 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | NR4A2 | P43354 | 3/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3627973 | 0.98 | ALDH1A1 (0.40) | ALDH1A1HSD17B10CFTRKDM4EPDE1C | |
| SCHEMBL7052811 | 0.80 | CYP1A2 (0.49) | ALDH1A1HSD17B10KDM4EGAAMAPT | |
| Hydrochloric Acid SCHEMBL6941254 | 0.79 | KDM4E (0.38) | ALDH1A1HSD17B10KDM4EGAAMAPT | |
| SCHEMBL11287001 | 0.79 | NR4A2 (0.41) | ALDH1A1KDM4EGAAMAPTNPSR1 | |
| SCHEMBL4046793 | 0.77 | NR4A2 (0.47) | NR4A2GRM1 | |
| SCHEMBL7560908 | 0.76 | CCNC (0.50) | ALDH1A1KDM4ETSHRTDP1 | |
| SCHEMBL875350 | 0.76 | KDM4E (0.39) | ALDH1A1HSD17B10KDM4EGAAMAPT | |
| SCHEMBL21561526 | 0.76 | TDP1 (0.38) | KDM4EGAAMAPTNPSR1TSHR | |
| SCHEMBL26113851 | 0.76 | NPSR1 (0.37) | ALDH1A1KDM4EGAANPSR1TSHR | |
| SCHEMBL16883380 | 0.76 | KDM4E (0.40) | ALDH1A1HSD17B10CFTRKDM4EGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4384506-A1 | PROCESS FOR POLYAMIDE SYNTHESIS | Design Therapeutics, Inc. (US) | 2024-06-19 | — | — | EP | disclosed |
| WO-2023244678-A1 | METHODS AND COMPOUNDS FOR MODULATING INHERITED GENETIC DISEASES | Design Therapeutics, Inc. (US) | 2023-12-21 | — | — | WO | disclosed |
| WO-2023133284-A2 | COMPOUNDS AND METHODS FOR TREATING FRIEDREICH'S ATAXIA | Design Therapeutics, Inc. (US) | 2023-07-13 | — | — | WO | disclosed |
| WO-2023014793-A1 | PROCESS FOR POLYAMIDE SYNTHESIS | Design Therapeutics, Inc. (US) | 2023-02-09 | — | — | WO | disclosed |
| EP-4100404-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. (US) | 2022-12-14 | — | — | EP | disclosed |
| WO-2021158707-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. (US) | 2021-08-12 | — | — | WO | disclosed |
| EP-2190826-A2 | 2-BIPHENYLAMINO-4-AMINOPYRIMIDINE DERIVATIVES AS KINASE INHIBITORS | IRM LLC (BM) | 2010-06-02 | — | — | EP | disclosed |
| WO-2009032668-A2 | 2 -BIPHENYLAMINO-4 -AMINOPYRIMIDINE DERIVATIVES AS KINASE INHIBITORS | IRM LLC (BM) | 2009-03-12 | — | — | WO | disclosed |
| WO-2002000649-A9 | SUBSTITUTED QUINAZOLINE DERIVATIVES AND THEIR USE AS INHIBITORS | ASTRAZENECA AB (SE) | 2007-09-20 | — | — | WO | disclosed |
| EP-1007729-A4 | COMPLEX FORMATION BETWEEN dsDNA AND OLIGOMER OF HETEROCYCLES | CALIFORNIA INST OF TECHN (US) | 2006-05-17 | — | — | EP | disclosed |
| EP-1307470-A2 | LINKED, SEQUENCE-SPECIFIC DNA-BINDING MOLECULES | UNIVERSITE DE GENEVE (CH) | 2003-05-07 | — | — | EP | disclosed |
| EP-1290198-A2 | VECTORS FOR DNA DELIVERY | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) | 2003-03-12 | — | — | EP | disclosed |
| WO-2002101073-A2 | ARYL-BENZIMIDAZOLE COMPOUNDS HAVING ANTIINFECTIVE ACTIVITY | GENESOFT PHARMACEUTICALS, INC. (US) | 2002-12-19 | — | — | WO | disclosed |
| WO-2002004476-A2 | LINKED, SEQUENCE-SPECIFIC DNA-BINDING MOLECULES | UNIVERSITE DE GENEVE (CH) | 2002-01-17 | — | — | WO | disclosed |
| WO-2001088160-A2 | VECTORS FOR DNA DELIVERY | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI, S.P.A. (IT) | 2001-11-22 | — | — | WO | disclosed |
| EP-1007729-A1 | COMPLEX FORMATION BETWEEN dsDNA AND OLIGOMER OF HETEROCYCLES | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2000-06-14 | — | — | EP | disclosed |
| EP-0991417-A1 | COMPLEX FORMATION BETWEEN DSDNA AND OLIGOMER OF HETEROCYCLES | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2000-04-12 | — | — | EP | disclosed |
| WO-1998050058-A1 | COMPLEX FORMATION BETWEEN DSDNA AND OLIGOMER OF HETEROCYCLES | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 1998-11-12 | — | — | WO | disclosed |
| WO-1998050582-A1 | COMPLEX FORMATION BETWEEN dsDNA AND OLIGOMER OF HETEROCYCLES | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 1998-11-12 | — | — | WO | disclosed |